Healthcare scale Lucid Group operates in healthcare marketing services with a global reach and a growing headcount, presenting opportunities to cross-sell integrated evidence-led programmes, AI-enabled insights, and cross-therapy consensus initiatives to larger pharma, biotech, and healthcare brands.

Strategic leadership Recent executive and boardroom changes, including a new CEO and board chair, signal strategic shifts. This creates openings for high-level engagements around strategic realignment, partnerships, and large-scale transformation programs that require creative storytelling and measurable impact.

US consolidation The launch of Lucid Group US and the unification of US agencies under one entity suggests a prime moment to pursue enterprise deals, regional expansions, and synchronized marketing/medical communications solutions across the US market.

Therapy impact Lucid emphasizes consensus programs across multiple therapy areas with potential reach to hundreds of millions of patients, indicating opportunities to offer real-world data programs, payer-oriented evidence, and adoption-focused commercialization services.

Operational growth Headcount growth and prior hiring from related tech and services ecosystems point to opportunities for scalable, tech-enabled engagement models, data analytics, and AI-powered insights to accelerate clients’ time-to-impact and optimize ROI.